1,947
Views
9
CrossRef citations to date
0
Altmetric
ORIGINAL ARTICLES: RADIOTHERAPY

68Ga-PSMA-PET/CT-directed IGRT/SBRT for oligometastases of recurrent prostate cancer after initial surgery

ORCID Icon, , , , , , , ORCID Icon, , , , & ORCID Icon show all
Pages 149-156 | Received 21 May 2019, Accepted 14 Sep 2019, Published online: 27 Sep 2019

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Anita M. Werensteijn-Honingh, Anne F. J. Wevers, Max Peters, Petra S. Kroon, Martijn Intven, Wietse S. C. Eppinga & Ina M. Jürgenliemk-Schulz. (2021) Progression-free survival in patients with 68Ga-PSMA-PET-directed SBRT for lymph node oligometastases. Acta Oncologica 60:10, pages 1342-1351.
Read now

Articles from other publishers (8)

Shamus Moran, Heather H. Cheng, Emily Weg, Eric H. Kim, Delphine L. Chen, Amir Iravani & Joseph E. Ippolito. (2024) Prostate-specific membrane antigen-positron emission tomography (PSMA-PET) of prostate cancer: current and emerging applications. Abdominal Radiology 49:4, pages 1288-1305.
Crossref
Gianluca Ingrosso, Marta Bottero, Carlotta Becherini, Saverio Caini, Emanuele Alì, Andrea Lancia, Piet Ost, Giuseppe Sanguineti, Shankar Siva, Thomas Zilli, Giulio Francolini, Rita Bellavita, Cynthia Aristei, Lorenzo Livi & Beatrice Detti. (2022) A systematic review and meta-analysis on non-metastatic castration resistant prostate cancer: The radiation oncologist's perspective. Seminars in Oncology 49:5, pages 409-418.
Crossref
Xianzhi Zhao, Tao Wang, Yusheng Ye, Jing Li, Xu Gao & Huojun Zhang. (2022) Stereotactic body radiotherapy (SBRT) versus androgen deprivation therapy (ADT) for oligometastatic prostate cancer: protocol for a prospective randomised control clinical trial. BMJ Open 12:9, pages e051371.
Crossref
Charlotte L. Deijen, Gerbert L. Vrijenhoek, Eva E. Schaake, Wouter V. Vogel, Luc M.F. Moonen, Floris J. Pos, Henk G. van der Poel & Gerben R. Borst. (2021) PSMA-11-PET/CT versus choline-PET/CT to guide stereotactic ablative radiotherapy for androgen deprivation therapy deferral in patients with oligometastatic prostate cancer. Clinical and Translational Radiation Oncology 30, pages 1-6.
Crossref
Rosario Mazzola, Giulio Francolini, Luca Triggiani, Giuseppe Napoli, Francesco Cuccia, Luca Nicosia, Lorenzo Livi, Stefano Maria Magrini, Matteo Salgarello & Filippo Alongi. (2021) Metastasis-directed Therapy (SBRT) Guided by PET-CT 18F-CHOLINE Versus PET-CT 68Ga-PSMA in Castration-sensitive Oligorecurrent Prostate Cancer: A Comparative Analysis of Effectiveness. Clinical Genitourinary Cancer 19:3, pages 230-236.
Crossref
Cedric Curt Cappel, Denise Dopcke & Jürgen Dunst. (2021) PSMA-PET/CT im primären Staging des Prostatakarzinoms. InFo Hämatologie + Onkologie 24:3, pages 28-30.
Crossref
Cedric Curt Cappel, Denise Dopcke & Jürgen Dunst. (2021) PSMA-PET-CT zum primären Staging von Patienten mit fortgeschrittenem ProstatakarzinomPSMA PET-CT for primary staging in patients with advanced prostate cancer. Strahlentherapie und Onkologie 197:3, pages 257-260.
Crossref
Maurits Wondergem, Friso M. van der Zant, Wouter A. M. Broos & Remco J. J. Knol. (2020) Clinical impact of PSMA PET in biochemically recurrent prostate cancer; a review of the literatureKlinische waarde van PSMA PET bij biochemisch recidiefprostaatcarcinoom; een review van de literatuur. Tijdschrift voor Urologie 10:6-7, pages 109-121.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.